23 October 2020 - - Canada-based biospecimen procurement CRO Trans-Hit Biomarkers Inc. has signed a partnership agreement with Laboratoires Nexelis Canada Inc. (Nexelis) to support prophylactic and therapeutic vaccine development programs sponsored by global pharmaceutical companies, innovative biotechnology companies, and governmental and non-governmental organizations including Bill and Melinda Gates Foundation and Coalition for Epidemic Preparedness Innovations, the organisation said.

Under the terms of the agreement, THB will manage Nexelis' biospecimen procurement activities, consolidating Nexelis' current sourcing channels with those of THB spanning over 20 countries worldwide.

With unrivaled expertise in immunology, and operating sites in North America (East and West Coast) and Europe, Nexelis is a provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields.

Our versatile team of scientists, working with our advanced technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines, anti-viral drugs, and immunotherapy, gene and cell therapy products.

Trans-Hit Biomarkers Inc is a worldwide biospecimen procurement CRO with the most extensive collection capability for biospecimens and clinical samples through an unrivalled worldwide partnered network of clinical partners and biobanks.

The company, led by a team with a solid background in biomedical research, advises and provides biopharma and diagnostic clients with the best solutions to help design, organize, and conduct sample collections in various fields including oncology, infectious and CNS diseases, among others.

THB manages the entire biospecimen acquisition process, from the initial sample request, to the moment the samples are delivered, and beyond. To learn more about THB, please, visit www.trans-hit.com.